.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,389,472

« Back to Dashboard

Details for Patent: 8,389,472

Title:Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
Abstract: The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.
Inventor(s): Baron; Alain D. (San Diego, CA), Kim; Dennis (San Diego, CA), Maggs; David G. (San Diego, CA), Wintle; Matthew (San Diego, CA)
Assignee: Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)
Filing Date:Aug 21, 2006
Application Number:12/063,712
Claims:1. A method for treating nonalcoholic steatohepatitis in a human in need thereof comprising subcutaneously administering to the human a therapeutically effective amount of exendin-4 to treat the nonalcoholic steatohepatitis in the human.

2. The method of claim 1, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.

3. A method for treating nonalcoholic steatohepatitis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of exendin-4 to treat the nonalcoholic steatohepatitis in the subject.

4. The method of claim 3, wherein the therapeutically effective amount is an amount that maintains an average plasma concentration of exendin-4 of at least 10 pg/ml for at least 12 hours.

5. The method of claim 3, wherein the exendin-4 is parenterally administered to the subject.

6. The method of claim 3, wherein the subject is a human.

7. The method of claim 3, wherein the exendin-4 is administered to the subject by subcutaneous injection.

8. The method of claim 3, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.

9. A method for treating nonalcoholic fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of exendin-4 to treat the nonalcoholic fatty liver disease in the subject.

10. The method of claim 9, wherein the therapeutically effective amount is an amount that maintains an average plasma concentration of exendin-4 of at least 10 pg/ml for at least 12 hours.

11. The method of claim 9, wherein the exendin-4 is parenterally administered to the subject.

12. The method of claim 9, wherein the subject is a human.

13. The method of claim 9, wherein the exendin-4 is administered to the subject by subcutaneous injection.

14. The method of claim 9, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.

15. A method for treating nonalcoholic fatty liver disease in a human in need thereof comprising subcutaneously administering to the human a therapeutically effective amount of exendin-4 to treat the nonalcoholic fatty liver disease in the human.

16. The method of claim 15, further comprising administering a therapeutically effective amount of a dipeptidyl peptidase-IV inhibitor, metformin, a sulfonylurea, or a combination of two or more thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc